Breast cancer drug pricing options: Slash prices or forget market access
This article was originally published in Scrip
Executive Summary
With an increasingly competitive market evolving, and biosimilar Herceptin (trastuzumab) cresting the horizon, novel HER2-positive breast cancer drugs are facing a difficult time for positioning and market access. In fact, there are only two real pricing options emerging; either offer payers worldwide hefty discounts and other novel pricing schemes, or forget the opportunity to compete altogether.